Scholarlink

Objective <p>The C-reactive protein-triglyceride-glucose index (CTI) has emerged as a novel biomarker to assess metabolic-inflammatory disorders. However, the relationship between CTI and cardiovascular disease (CVD) in people living with HIV (PLWH) remains unexplored.</p> Methods <p>This cross-sectional study enrolled 505 PLWH who initiated antiretroviral therapy (ART) at Beijing Ditan Hospital between January 2016 and December 2020. Multivariate logistic regression models were constructed to assess the relationship between CTI and CVD prevalence, adjusting for potential confounding factors. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance of CTI for CVD, with the area under the curve (AUC) serving as the primary metric. Furthermore, restricted cubic spline (RCS) analysis was performed to explore the dose–response relationship between CTI and CVD.</p> Results <p>After adjusting for potential confounders, higher CTI was significantly associated with an increased prevalence of CVD. Each standard deviation (SD) increase in CTI was associated with a 189.0% higher prevalence of CVD (odds ratio [OR] = 2.890, 95% confidence interval [CI] = 1.805–4.598, <i>P</i> &lt; 0.001). CTI yielded satisfactory discriminative performance for CVD (AUC = 0.763), with comparable predictive ability to the triglyceride-glucose (TyG) index (AUC = 0.731) and markedly better performance than C-reactive protein (AUC = 0.581). Subgroup and interaction analysis indicated that the association between CTI and CVD remained consistent across subgroups stratified by gender, smoking, drinking, hyperlipidemia, hypertension, and diabetes mellitus, with some variations observed across age groups and body mass index categories. RCS analysis showed a significantly higher prevalence of CVD when CTI values exceeded 8.9.</p> Conclusion <p>As a novel composite biomarker integrating metabolic and inflammatory signatures, CTI is independently associated with CVD prevalence in PLWH. Incorporating CTI monitoring into routine clinical practice may improve the accuracy of CVD stratification and facilitate the development of personalized preventive and therapeutic strategies for this high-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

C-reactive protein-triglyceride-glucose index is associated with cardiovascular disease in people living with HIV

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月6日

查看全文
  • Yanyan Li,
  • Zhongyi Zhang,
  • Rui Qiao,
  • Xin Li

摘要

Objective

The C-reactive protein-triglyceride-glucose index (CTI) has emerged as a novel biomarker to assess metabolic-inflammatory disorders. However, the relationship between CTI and cardiovascular disease (CVD) in people living with HIV (PLWH) remains unexplored.

Methods

This cross-sectional study enrolled 505 PLWH who initiated antiretroviral therapy (ART) at Beijing Ditan Hospital between January 2016 and December 2020. Multivariate logistic regression models were constructed to assess the relationship between CTI and CVD prevalence, adjusting for potential confounding factors. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance of CTI for CVD, with the area under the curve (AUC) serving as the primary metric. Furthermore, restricted cubic spline (RCS) analysis was performed to explore the dose–response relationship between CTI and CVD.

Results

After adjusting for potential confounders, higher CTI was significantly associated with an increased prevalence of CVD. Each standard deviation (SD) increase in CTI was associated with a 189.0% higher prevalence of CVD (odds ratio [OR] = 2.890, 95% confidence interval [CI] = 1.805–4.598, P < 0.001). CTI yielded satisfactory discriminative performance for CVD (AUC = 0.763), with comparable predictive ability to the triglyceride-glucose (TyG) index (AUC = 0.731) and markedly better performance than C-reactive protein (AUC = 0.581). Subgroup and interaction analysis indicated that the association between CTI and CVD remained consistent across subgroups stratified by gender, smoking, drinking, hyperlipidemia, hypertension, and diabetes mellitus, with some variations observed across age groups and body mass index categories. RCS analysis showed a significantly higher prevalence of CVD when CTI values exceeded 8.9.

Conclusion

As a novel composite biomarker integrating metabolic and inflammatory signatures, CTI is independently associated with CVD prevalence in PLWH. Incorporating CTI monitoring into routine clinical practice may improve the accuracy of CVD stratification and facilitate the development of personalized preventive and therapeutic strategies for this high-risk population.